HIV / AIDS

Read and watch the infectious disease trial data shared this week.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, review strategies for determining whether drug resistance is the primary reason for suboptimal treatment response or adherence.

Thought leaders discuss when and how to approach drug resistance and steps to ensure long-term treatment success.

Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.

Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss factors that shape treatment approaches, including tolerability and treatment adherence.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, explore the ways in which drug-resistance mutations impact treatment efficacy.

Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, examine the many factors associated with increased risk of HIV, including substance abuse, unstable housing/food situations, and mental illness.

Joseph Eron, MD and Daniel R. Kuritzkes, MD, discuss how to define “heavily treatment-experienced” and also discuss the prevalence of various types of drug resistance.

The study authors called eliminating barriers to HIV care and treatment a national priority.

How do we increase HIV PrEP uptake? “I think the biggest takeaway here is that people need options,” said Travis Sanchez, DVM, MPH.

Pregnant people taking dolutegravir were more likely to achieve HIV viral suppression and less likely to have a preterm birth than participants using other forms of ART.

With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

A retrospective study of a Colombian cohort examined the causes of antiretroviral switch in people living with HIV/AIDS, as well as the time to ART switch.

The phase IIb trial evaluated whether adding a novel regimen of monthly azithromycin to a daily dose of trimethoprim-sulfamethoxazole would decrease the rate of STI at time of delivery among pregnant women living with HIV in Cameroon.

CRISPR edit of proviral DNA tested as potential cure for HIV in first participant of phase 1/2 clinical trial.

The intervention included meeting with experts, texting services to improve and facilitate communication, and data collection and dissemination.

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.

This will include 3 trials to examine the therapy in different formulations in HIV studies.

Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.

There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.

Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.

Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.